Zomig 2.5mg Tablets, Zomig Rapimelt 2.5mg Orodispersible Tablets, Zomig Rapimelt 5mg Orodispersible Tablets, Zomig 5mg Nasal Spray
The links below will direct you to www.medicines.org.uk/emc, an external website providing information about medicines in the UK, including the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SPC).
The product information provided in this site is intended for residents of the UK only. The following documents are hosted externally. Grünenthal UK Ltd. is not responsible for the content of external sites.
- Zomig 2.5mg Tablets
- Zomig Rapimelt 2.5mg Orodispersible Tablets
- Zomig Rapimelt 5mg Orodispersible Tablets
- Zomig 5mg Nasal Spray
Contact for Medical Information, Reporting Safety and Quality Related Issues:
If you need more information about our products or wish to report an adverse event or product quality related issue, please contact our Medical Information department via email or telephone:Phone: 0870 351 8960
Adverse events should be reported:
If, as a patient, you get any side effects talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in the package leaflet. By reporting side effects you can help provide more information on the safety of this medicine. You can also report side effects directly via the Yellow Card scheme at http://www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Grunenthal Ltd., UK.
M--UK-11-18-0003 Date of Preparation February 2019